Hyperplasia and benign hypertrophy
Benignprostatic hypertrophy refers to an increase in the size of the prostate, which compresses the urethra while putting pressure on the bladder, which causes various problems of urination. At the age of 50, problems appear and at 60, 50% of men are affected. This percentage will gradually increase with age and at age 80, 90% of it is affected. On the other hand, about 1 in two men will suffer. This condition is not not of cancerous origin and does not increase the risk of prostate cancer, but also does not prevent its development.
Hyperplasia or benign prostatic hyperplasia for its part refers to the development of a quantity of constituent cells of a tissue or an organ too important compared to normal or the formation of an abnormal tissue in the middle of the normal tissue. In addition to the prostate, hyperplasia can affect several organs including the tonsils in case of angina glands.
Precancerous condition of the prostate
Intraepithelial neoplasia of the prostate (PIN) is a highly recognized precancerous condition of the prostate. It can occur at the same time in several different places on the prostate (multifocal). Pin often occurs in the peripheral area of the prostate, where most prostate cancers are found.
Not all PINs turn into prostate cancer. It is difficult to predict if the PIN will become cancerous and it can take more than 10 years for a PIN to turn into prostate cancer. (1)
Proliferative inflammatory atrophy (PIA)
Small atypical acinar proliferation (ASAP)
ASAP is an abnormal growth of glandular cells that can turn into prostate cancer. In men with ASAP, the risk of finding prostate cancer during a biopsy is about 40-50%. (3)
Prostate cancer is a malignant tumour that starts in prostate cells and can metastasize to other parts of the body. Prostate cancer is the most common cancer among men in Canada. It usually develops slowly and can often be removed completely or treated successfully.
Treatment for prostate cancer is given by cancer specialists, oncologists. Some specialize in surgery, others in radiation therapy or chemotherapy (drugs). Only those doctors who are familiar with the history and health check-up of the affected person can determine a treatment plan.
Reference: (1), (2), (3): Canadian Cancer Society, prostate cancer for which this article is the source.
Support reading: Health Passport, benign prostatic hypertrophy
We strongly suggest that you visit the website of the Canadian Cancer Society www.cancer.ca which is intended to be the most complete and which deals with the subject in a very scientific and above all very professional way. All the information mentioned above is more complete. It is the same with Passeport Santé.
Our product, the C&B Prostate Formula, is a prevention product. Its raw materials have been clinically tested on humans. The results were conclusive on the effectiveness of prevention. To know more about the product: C&B Liquid Prostate Formula 250ml